Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - grazoprevirum, elbasvirum - zepatier compresse rivestite con film - grazoprevirum 100 mg ut grazoprevirum monohydricum, elbasvirum 50 mg, natrii laurilsulfas, copovidonum, mannitolum, carmellosum natricum conexum, natrii chloridum, silica colloidalis anhydrica, magnesii stearas, hypromellosum, tocofersolanum, cellulosum microcristallinum, lactosum monohydricum 71.24 mg, Überzug: cera carnauba lactosum monohydricum 15.78 mg, hypromellosum, triacetinum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 69.85 mg. - chronische epatite c - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - epatite c, cronica - antivirali per uso sistemico - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Unione Europea - italiano - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - reiezione del trapianto - immunosoppressori - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

aspen pharma trading limited - analoghi della purina - analoghi della purina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - azatioprina - azatioprina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - azatioprina - azatioprina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

alfasigma s.p.a. - azatioprina - azatioprina

Unione Europea - italiano - EMA (European Medicines Agency)

biopartners gmbh - recombinant human interferon alfa-2a - epatite c, cronica - immunostimolanti, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.

Unione Europea - italiano - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir di sodio, rilpivirine hydrochloride - infezioni da hiv - antivirali per uso sistemico - juluca è indicato per il trattamento del virus dell'immunodeficienza umana di tipo 1 (hiv-1) infezione negli adulti che sono virologicamente soppressi (hiv-1 rna.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - lamivudina e abacavir - lamivudina e abacavir